Dongin (Donoven) Kim, Ph.D.

---

Publications & Presentations

6. Kang C, Ren X, Lee D, Ramesh R, Nimmo S, Yang-Hartwich Y, Kim D. Harnessing small extracellular vesicles for pro-oxidant delivery: novel approach for drug-sensitive and resistant cancer therapy. Journal of Controlled Release/ELSEVIER. 2024; 365 : 286-300

7. Rana S, Kang C, Allred J, Medina-Duran J H, Canova A, Sherry D, Woller D A, Kim D, Song H. Differential responses to double-stranded RNA injection and feeding in Mormon cricket (Orthoptera: Tettigoniidae) . Journal of Insect Science/Oxford Academic. 2023; 23

8. Ren X, Kang C, Garcia-Contreras L, Kim D. Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications. International Journal of Molecular Sciences/MDPI. 2023; 24 : 8166

9. Kang C, Ren X, Garcia-Contreras L, Kim D. Understanding of Ovarian Cancer Cell-Derived Exosome Tropism for Future Therapeutic Applications. International Journal of Molecular Sciences . 2023; 24 : 8166

10. Kim D. A Kidney-Targeted Nanoparticle to Augment Renal Lymphatic Density Decreases Blood Pressure in Hypertensive Mice. Pharmaceutics/MDPI. 2022; 14 : 84

Grants

1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.

2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.

3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.

5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

Awards and Honors

no results

Education

1. Degree: Ph D. University of Utah. Date: 2009.


2. Degree: MS. University of Florida. Date: 2002.


3. Degree: BS. Ajou University. Date: 1999.

Administrative Assignments

no results